Date of Publication: 20-Feb-2026
INTELLIGENCE OVERVIEW
Agency: EMA
The European Medicines Agency (EMA), through its Committee for Veterinary Medicinal Products (CVMP), has released a draft guideline outlining the quality requirements for mRNA vaccines intended for veterinary use. This marks an important regulatory milestone as mRNA technology continues to expand beyond human vaccines into veterinary medicine.
mRNA vaccines have gained significant attention due to their safety profile, flexibility, and ability to stimulate robust immune responses. Unlike traditional vaccines, mRNA vaccines do not involve live pathogens and offer advantages such as scalable manufacturing, rapid development, and reduced contamination risks. These characteristics make them especially valuable for responding to emerging infectious diseases in animals.
The draft guideline provides detailed recommendations on the quality data requirements that must be included in marketing authorisation applications for veterinary mRNA vaccines. It covers critical aspects such as starting materials, active substance characterization, manufacturing processes, analytical controls, and finished product specifications. The guideline also emphasizes the importance of demonstrating batch consistency, ensuring product stability, and validating delivery systems such as lipid nanoparticles, which protect mRNA and facilitate its delivery into target cells.
In addition, the guidance highlights the need for comprehensive characterization of the mRNA sequence, structural integrity, purity, and functionality. Manufacturers are expected to establish appropriate potency assays, impurity controls, and stability testing programs to ensure product safety, quality, and efficacy throughout the product lifecycle.
This draft guidance reflects the growing regulatory focus on emerging vaccine technologies and aims to support the development and approval of high-quality mRNA vaccines for veterinary use. It also aligns with Regulation (EU) 2019/6, ensuring consistent regulatory expectations across the European veterinary medicinal product framework.
The consultation period is open until 31 August 2026, providing stakeholders an opportunity to submit comments and contribute to the finalization of this important guideline.
KEYWORDS: mRNA Vaccines, Quality Standards, Product Characterization
REFERENCE: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-aspects-mrna-vaccines-veterinary-use_en.pdf